Study finds key differences with 2 vision disorders in children
Vision problems more severe in kids with NMOSD than in those with MOGAD
Written by |
Children with neuromyelitis optica spectrum disorder (NMOSD) are more likely to have severe vision problems and incomplete visual recovery than those with the related condition myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
That’s according to a review of published studies involving children with NMOSD associated with antibodies against the aquaporin-4 (AQP4) protein — the most common type of NMOSD-driving antibodies — and those with MOGAD.
Differences in symptoms, imaging findings, and antibody testing may help doctors distinguish the two diseases earlier and choose the most appropriate treatment before permanent vision damage occurs, the study showed.
“Overall, this mapping provides a coherent and clinically applicable framework for diagnostic and therapeutic decision-making in children and adolescents presenting with acute optic neuropathy,” the researchers wrote. Optic neuropathy, a shared feature of NMOSD and MOGAD, refers to damage to the optic nerve, which relays signals between the eyes and the brain.
The study, “Comparative immunopathology and clinical features of MOGAD and AQP4-IgG NMOSD in children: A scoping review,” was published in Multiple Sclerosis and Related Conditions.
Autoimmune attacks
NMOSD and MOGAD are rare autoimmune diseases marked by an abnormal immune response against healthy cells of the brain and spinal cord. These autoimmune attacks often cause optic nerve inflammation (optic neuritis), which can lead to vision loss.
NMOSD is caused in most cases by self-reactive antibodies that target AQP4, a protein on nerve-supporting cells. MOGAD is linked to self-reactive antibodies against myelin oligodendrocyte glycoprotein (MOG), a molecule found on the fatty protective coating surrounding nerve fibers.
While standardization of diagnostic criteria has improved discrimination between the two conditions, “challenges remain in pediatric practice, particularly in cases with low antibody [levels] or ambiguous clinical presentations,” the researchers wrote.
The four researchers in Greece systematically reviewed studies published through October 2025 describing pediatric cases of optic neuritis caused by AQP4-related NMOSD or MOGAD, including clinical features, imaging findings, antibody testing, treatments, and visual and relapse outcomes.
Available data showed that children with AQP4-related NMOSD present a different clinical pattern than those with MOGAD.
Based on clinical and imaging data, the team found that MOGAD commonly causes inflammation in the front part of the optic nerve, frequently affects both eyes, and is associated with swelling of the optic disc, a small, circular region where the optic nerve enters the back of the eye.
Children with MOGAD often respond well to corticosteroids, a type of anti-inflammatory and immunosuppressive medications, and may recover good vision.
In contrast, AQP4-related NMOSD frequently involves the back of the optic nerve, results in more severe vision problems and relapses, and is associated with a lower chance of complete visual recovery.
The researchers also found that, outside Asia, children with isolated optic neuritis are much more likely to have self-reactive antibodies against MOG than against AQP4. This information may help doctors determine which condition is more likely, but antibody results should always be interpreted alongside clinical and imaging findings, the team noted.
The study also highlighted the diagnostic value of optical coherence tomography (OCT), a noninvasive imaging technique that captures detailed images of the eye, including the retina, the back part of the eyeball that contains a layer of light-sensing cells.
In children with AQP4-related NMOSD, OCT often showed permanent shrinkage (atrophy) of retinal tissue, which may be associated with worse long-term vision or poor functional recovery. In contrast, those with MOGAD frequently have swelling of the retinal nerve fibers during active inflammation, which usually decreases after the inflammation resolves.
These differences reflect the distinct molecular mechanisms underlying the two diseases, the team said.
The scientists said OCT may become an important tool not only for diagnosis but also for follow-up, helping doctors monitor changes over time. Imaging and OCT “emerged as central pillars of early differential diagnosis,” they wrote, because OCT patterns may provide early clues about the underlying disease before permanent vision damage develops.
Treatment approaches also differed between the two conditions. Doctors often used stronger immunosuppressive therapies for a longer period in children with AQP4-related NMOSD, because repeated relapses can lead to more severe and permanent vision loss.
The researchers said these differences are likely related to how each disease activates the immune system, with anti-AQP4 antibodies causing more severe immune-mediated damage to nerve-supporting cells.
Overall, the findings suggest that combining clinical features with MRI, OCT, and antibody testing may help doctors diagnose children earlier, better distinguish AQP4-related NMOSD from MOGAD, and select treatments that best match each disease to improve long-term visual outcomes.
Because current evidence is mainly based on small and retrospective studies, the team said, larger trials following patients over time are needed to better define the best approaches for preventing relapses and preserving vision.
